Minimally-invasive treatments for benign thyroid nodules : a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group by E. Papini et al.
International Journal of Hyperthermia
ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://www.tandfonline.com/loi/ihyt20
Minimally-invasive treatments for benign thyroid
nodules: a Delphi-based consensus statement
from the Italian minimally-invasive treatments of
the thyroid (MITT) group
Enrico Papini, Claudio Maurizio Pacella, Luigi Alessandro Solbiati, Gaetano
Achille, Daniele Barbaro, Stella Bernardi, Vito Cantisani, Roberto Cesareo,
Arturo Chiti, Luca Cozzaglio, Anna Crescenzi, Francesco De Cobelli, Maurilio
Deandrea, Laura Fugazzola, Giovanni Gambelunghe, Roberto Garberoglio,
Gioacchino Giugliano, Livio Luzi, Roberto Negro, Luca Persani, Bruno
Raggiunti, Francesco Sardanelli, Ettore Seregni, Martina Sollini, Stefano
Spiezia, Fulvio Stacul, Dominique Van Doorne, Luca Maria Sconfienza &
Giovanni Mauri
To cite this article: Enrico Papini, Claudio Maurizio Pacella, Luigi Alessandro Solbiati, Gaetano
Achille, Daniele Barbaro, Stella Bernardi, Vito Cantisani, Roberto Cesareo, Arturo Chiti, Luca
Cozzaglio, Anna Crescenzi, Francesco De Cobelli, Maurilio Deandrea, Laura Fugazzola, Giovanni
Gambelunghe, Roberto Garberoglio, Gioacchino Giugliano, Livio Luzi, Roberto Negro, Luca
Persani, Bruno Raggiunti, Francesco Sardanelli, Ettore Seregni, Martina Sollini, Stefano Spiezia,
Fulvio Stacul, Dominique Van Doorne, Luca Maria Sconfienza & Giovanni Mauri (2019) Minimally-
invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from
the Italian minimally-invasive treatments of the thyroid (MITT) group, International Journal of
Hyperthermia, 36:1, 376-382, DOI: 10.1080/02656736.2019.1575482
To link to this article:  https://doi.org/10.1080/02656736.2019.1575482
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC
Published online: 26 Mar 2019.
Submit your article to this journal 
Article views: 388
View Crossmark data
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ihyt20
Citing articles: 1 View citing articles 
Minimally-invasive treatments for benign thyroid nodules: a Delphi-based
consensus statement from the Italian minimally-invasive treatments of the
thyroid (MITT) group
Enrico Papinia, Claudio Maurizio Pacellab, Luigi Alessandro Solbiatic,d , Gaetano Achillee, Daniele Barbarof,
Stella Bernardig,h, Vito Cantisanii, Roberto Cesareoj, Arturo Chitic,d, Luca Cozzagliod, Anna Crescenzik,
Francesco De Cobellil, Maurilio Deandream, Laura Fugazzolan,o, Giovanni Gambelunghep, Roberto Garberoglioq,
Gioacchino Giuglianor, Livio Luzio,s, Roberto Negrot, Luca Persanin,o, Bruno Raggiuntiu, Francesco Sardanellio,v,
Ettore Seregniw, Martina Sollinic, Stefano Spieziax, Fulvio Staculg, Dominique Van Doorney,
Luca Maria Sconfienzao,z and Giovanni Mauriaa
aDipartimento di Endocrinologia, Ospedale Regina Apostolorum, Albano Laziale, Italy; bDipartimento di Imaging Diagnostico e Radiologia
Interventistica, Ospedale Regina Apostolorum, Albano Laziale, Italy; cHumanitas University, Pieve Emanuele, Milan, Italy; dHumanitas Clinical
and Research Center IRCCS, Rozzano, Italy; eUnita Operativa ORL, IRCCS Oncologico "Giovanni Paolo II", Bari, Italy; fU.O. Endocrinologia ASL
Nordovest Toscana, Toscana, Italy; gAzienda Sanitaria Universitaria Integrata Trieste, Trieste, Italy; hUniversita degli Studi di Trieste, Trieste,
Italy; iPoliclinico Umberto I, Universita Sapienza, Roma, Italy; jThyroid and metabolic bone diseases center, Ospedale Santa Maria Goretti,
Latina, Italy; kUOC Anatomia Patologica, Policlinico Universitario Campus Bio-Medico, Roma, Italy; lOspedale San Raffaele, Universita Vita e
Salute, Milano, Italy; mEndocrinologia, Ospedale Mauriziano Torino, Torino, Italy; nIstituto Auxologico Italiano IRCCS, Milano, Italy; oUniversita
degli Studi di Milano, Milano, Italy; pAzienda Ospedaliero-Universitaria di Perugia, Perugia, Italy; qOspedale Citta della Salute Torino,
Dipartimento Universitario di Endocrinologia e Malattie Metaboliche, Torino, Italy; rDepartment of Head and Neck, Istituto Europeo di
Oncologia, IRCCS, Milano, Italy; sIRCCS Policlinico San Donato, UOC Endocrinologia e Malattie Metaboliche, San Donato Milanese, Italy; tUO
Endocrinologia PO "V. Fazzi", Lecce, Italy; uUOC Endocrinologia ASL Teramo, Teramo, Italy; vIRCCS Policlinico San Donato, San Donato
Milanese, Italy; wFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; xUnita Operativa di Chirurgia Endocrina ed Ecoguidata,
Ospedale del Mare, ASL Napoli1 centro, Napoli, Italy; yAME Associazione Medici Endocrinologi, Udine, Italy; zIRCCS Istituto Ortopedico
Galeazzi, Milano, Italy; aaDivision of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy
ABSTRACT
Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless
symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an
increasing role in the management of nodules causing local symptoms. In February 2018, the Italian
MIT Thyroid Group was founded to create a permanent cooperation between Italian and international
physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted
this list of statements based on literature review and consensus opinion of interdisciplinary experts to
facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1)
Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol
injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspir-
ation ¼ 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist
after ethanol ablation (LoE ¼ 4); (#3) Double cytological benignity confirmation is needed before ther-
mal ablation (LoE ¼ 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS
3) and in autonomously functioning nodules (LoE ¼ 2); (#5) Thermal ablation may be proposed as
first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE ¼ 2); (#6) Thermal
ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/
not eligible for surgery (LoE ¼ 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal
ablation (LoE ¼ 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially
resolve (LoE ¼ 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before
second ablation (LoE ¼ 5); (#10) Thermal ablation is an option for autonomously functioning nodules
in patients refusing/not eligible for radioiodine or surgery (LoE ¼ 2); (#11) Small autonomously func-
tioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and
80% nodule volume ablation is expected (LoE ¼ 3).
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Introduction
Benign thyroid nodules are a common occurrence in the
general population and usually do not require treatment
unless symptomatic [1]. In this case, patients generally report
local compressive symptoms or esthetic concerns, due to the
enlarging size of the nodule. Treatment options currently
include open or minimally invasive surgery, aspiration with
or without ethanol injection for cystic nodules, and thermal
ablations. In autonomously functioning thyroid nodules
(AFTNs), thyroid function is also affected and in these cases,
pharmacological therapy and/or radioiodine ablation are also
traditionally indicated [2].
Over the last years, ultrasound (US)-guided minimally
invasive treatment (MIT) (including chemical ablation and
energy-based ablations) gained an increasing role in the
management of benign thyroid nodules [3]. They have pro-
ven efficacy and safety for the management of compressive
symptoms and the improvement of esthetic concerns [4–9]
and are also demonstrating a promising role in the treat-
ment of selected AFTNs [10–14].
In February 2018, a meeting involving different specialists
with specific expertise in the use of MIT for thyroid nodules
was held in Milan, Italy [15]. It included dedicated radiolog-
ists, endocrinologists, nuclear medicine physicians, patholo-
gists, and surgeons who founded the Italian MIT Thyroid
(MITT) Group. This interdisciplinary group had the purpose of
creating a network between Italian and international physi-
cians who are dedicated to clinical research and care in the
field of MIT of thyroid nodules [15].
The purpose of this document drafted by the Italian MITT
Group was to provide a series of statements based on litera-
ture review and consensus opinion of interdisciplinary
experts to facilitate both the diffusion and the appropriate
use of MIT for the management of thyroid nodules in clin-
ical practice.
Materials and methods
Expert selection
For this consensus, an interdisciplinary board of 29 physi-
cians with specific expertise in the management of thyroid
nodules was appointed by the Italian MITT Group for their
proven experience in clinical practice and research on the
topic. The panel included radiologists, endocrinologists,
nuclear medicine physicians, pathologists, and surgeons.
Literature search and evaluation
After a thorough review of current literature, two authors
(GM and LMS) drafted a list of statements addressing the
most relevant questions on the use of MIT for thyroid nod-
ules. For each statement, literature evidence was assessed,
with a search on major online databases (MEDLINE, Web of
Science, EMBASE, and Google, with search terms (thyroid
ablation) OR (thyroid radiofrequency) OR (thyroid ethanol)
OR (thyroid laser) OR (thyroid microwave) OR (thyroid high-
intensity focused ultrasound) OR (thyroid radioiodine) OR
(thyroid fine-needle aspiration and their expansions), and lev-
els of evidence were assigned according to the criteria pro-
posed by the Oxford Center of Evidence-Based Medicine in
2011 [16].
Consensus process
The Delphi method was used for the consensus process on
the clinical use of MITT. This system consists of a sequence
of structured group rounds designed to survey the expert
opinion on potentially controversial topics and to reach a
final shared agreement [17,18]. Thus, in this process, each
participant was asked to agree, disagree, or abstain with the
proposed statements and the contributors had also the
opportunity to provide comments on each topic to appropri-
ately improve the statements. Finally, the AGREE II instru-
ment (a specific tool for assessing the quality and reporting
of practice guidelines) was used to verify the minimum qual-
ity requirements of the produced document [19,20]. An elec-
tronic questionnaire was built on the Google Forms platform
(Google LLC, CA) and was disseminated to all the
participants.
Two Delphi rounds were initially performed and a final
document was prepared to be submitted for publication.
After the manuscript was sent back for revisions, the refer-
ees’ comments were evaluated, the text was modified
accordingly, and a third Delphi round was performed. The
detailed consensus process is represented in Figure 1.
Statistical analysis
For each statement, the consensus opinion was established
at the end of the Delphi process. The consensus was consid-
ered as strong when >95% participants agreed, while it was
considered as broad when >80% but less than 95% agreed
on each statement [21].
The paper was then prepared based on the results of the
Delphi process and circulated via email among all partici-
pants for its final approval.
Statements
Statement #1. Predominantly cystic (51–90% of fluid compo-
nent) or cystic (>90% of fluid component) thyroid nodules
that become symptomatic should first undergo US-guided
percutaneous aspiration for both diagnostic and therapeutic
purposes, and image-guided ethanol ablation in case
of relapse
Summary of evidence. Predominantly cystic or purely cys-
tic thyroid nodules are a common clinical finding that does
not require treatment unless symptomatic. In case of com-
pressive symptoms or cosmetic concerns, the use of MIT can
provide a clinically significant benefit. Simple aspiration, US-
guided ethanol ablation, and thermal ablation have been
proposed for the management of cystic nodules. Current evi-
dence demonstrates that the outcomes of ethanol ablation
are superior to both conservative treatment [22] and simple
aspiration [4,23–25], while are nearly equivalent to thermal
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ablation [26,27], a procedure that is more complicated and
expensive. Thus, US-guided ethanol ablation is the most
appropriate procedure for relapsing cysts in terms of efficacy,
invasiveness, rapidity, and costs [28].
Level of evidence: 2
Level of agreement: strong (agree, n¼ 28; abstain, n¼ 1;
disagree, n¼ 0)
Statement #2. In symptomatic predominantly cystic thyroid
nodules, image-guided thermal ablation should be consid-
ered as an option when local symptoms persist after etha-
nol ablation.
Summary of evidence. A similar efficacy of ethanol abla-
tion and thermal ablation has been reported in the
treatment of predominantly cystic thyroid nodules [26,27].
However, thermal ablation should be considered as a further
therapeutic option in cystic lesions that relapse after ethanol
ablation or that would remain symptomatic due to the
residual solid component [29–31]. Thus, the use of thermal
ablation as a second line of treatment seems to be appropri-
ate in selected patients with symptoms persistence after
ethanol ablation.
Level of evidence: 4
Level of agreement: strong (agree, n¼ 28; abstain, n¼ 1;
disagree, n¼ 0)
Statement #3. A double cytological confirmation of benig-
nity should be obtained prior to image-guided thermal abla-
tion of thyroid nodules.
Summary of evidence. Generally, a double cytological con-
firmation should be obtained in thyroid nodules prior to
thermal ablation to rule out the risk of missing malignancy
[28,32]. A low rate (<3%) of false negative results has been
reported after a single fine needle aspiration, so generally, a
repeated aspiration after benign report is suggested, unless
US appearance of low risk of malignancy. However, as con-
cerns remain regarding a possible higher rate of false nega-
tive results, particularly in large nodules, double aspiration is
suggested before image-guided thermal ablation of a thyroid
nodule [33–35].
Level of evidence: 2
Level of agreement: strong (agree, n¼ 29; abstain, n¼ 0;
disagree, n¼ 0)
Statement # 4. A single cytological sample can be consid-
ered adequate to confirm nodule benignity if the US appear-
ance is at low risk of malignancy (EU-TIRADS 3) and
in AFTN.
Summary of evidence. Risk stratification at US is a crucial
predictive factor for thyroid nodule management. In this set-
ting, the EU-TIRADS system has been proven to be a valu-
able tool. Thyroid nodules classified as EU-TIRADS 3 have
been proven to have a low risk of malignancy, which ranges
between 2% and 4% [36,37]. In nodules that demonstrate
both cytological and US low-risk features, the risk of a false
negative result at cytology is definitely low, probably ranging
from 1% to 3%. Similarly, the risk of malignancy in AFTNs is
low in the adult population [38]. Therefore, in these low-risk
nodules, a single negative cytological examination may be
sufficient to candidate patients for thermal ablation [39–42].
Conversely, MIT management of AFTNs with TIR 3 A cytology
is still unsettled.
Level of evidence: 2
Level of agreement: strong (agree, n¼ 29; abstain, n¼ 0;
disagree, n¼ 0)
Statement #5. Thermal ablation may be proposed as a first-
line treatment for solid nonfunctioning thyroid nodules that
are benign at cytology when they become symptomatic.
Summary of evidence. Traditionally, open thyroidectomy
is the standard of care for benign thyroid nodules presenting
with cosmetic and/or compressive issues, even though
benign at cytology [43]. Limitations of surgery are the fre-
quent need for replacement therapy, the risk of
Figure 1. Flowchart of the Delphi consensus process used in the pre-
sent document.
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complications, and the elevated costs [28]. Thermal ablation
is an effective outpatient procedure, with high technical
feasibility [6], elevated clinical success rate [7,8], low fre-
quency of minor (0.5–4%) [7,9] and major complications (less
than 3.9%) [6], and outcomes sustained up to five years
[7,44–47]. A few comparative studies between thermal abla-
tion and open thyroidectomy showed that the former
resulted in shorter operation time, no need of hospitalization,
and absence of post-treatment scar [48], less complications
and side effects, no functional changes, higher patients’ satis-
faction [48–53] and, as a whole, lower direct and long-
term costs.
Level of evidence: 2
Level of agreement: strong (agree, n¼ 28; abstain, n¼ 0;
disagree, n¼ 1)
Statement #6. Thermal ablation may be proposed as a treat-
ment for nonfunctioning benign multinodular goiter only in
patients who refuse or who cannot undergo surgery.
Summary of evidence. Currently, a single paper reported
about the use of thermal ablation in multinodular goiter,
showing that sequential treatment in the same session is
effective and safe even if with longer procedure time and
less tolerable pain in the day after treatment [54]. Due to the
limited evidence and the burdensome modality of treatment,
thermal ablation should be considered as a possible thera-
peutic option only in patients with well-defined dominant
nodules who refuse or cannot undergo surgery [4].
Level of evidence: 5
Level of agreement: strong (agree, n¼ 28; abstain, n¼ 0;
disagree, n¼ 1)
Statement #7. Thyroid nodules treated with thermal ablation
should be routinely followed-up with clinical and US
examination.
Summary of evidence. US is the most reliable method to
evaluate thyroid nodules, both in the pretreatment setting
and after thermal ablation [7,9,45,55,56]. Contrast-enhanced
US provides a clear representation of parenchymal vascular-
ization immediately after thermal ablation, when the pres-
ence of gas bubbles generated by ablation may impair the
assessment of the treated area [57,58]. During follow-up, sim-
ple B-mode US nodule evaluation is generally not adequate
to distinguish between the still vital part of the nodule and
the area of ablated tissue. So, the use of other modalities
such as color-Doppler or contrast-enhanced US may be con-
sidered for the detection of the still vital part of the treated
nodule [4,52,59].
Level of evidence: 2
Level of agreement: strong (agree, n¼ 27; abstain, n¼ 1;
disagree, n¼ 1)
Statement #8. In case of incomplete symptom resolution,
symptom relapse, or nodule regrowth, a re-treatment with
thermal ablation may be considered.
Summary of evidence. The clinical purpose of thermal
ablation is the improvement of local symptoms and signs
due to thyroid nodule pressure. If symptoms persist after ini-
tial therapy [60–62], an additional treatment may be per-
formed, which usually results in symptom improvement.
Re-treatment after thermal ablation is reported as required in
a minority of cases [60,63,64]. The proper timing of re-treat-
ment is presently unsettled.
Level of evidence: 2
Level of agreement: strong (agree, n¼ 29; abstain, n¼ 0;
disagree, n¼ 0)
Statement # 9. In case of nodule regrowth, a new cyto-
logical assessment is suggested before the second ablation
Summary of evidence. No papers specifically addressed
the risk of malignancy in nodules regrowing after image-
guided thermal ablation. However, as nodule regrowth
(defined as 50% nodule volume increase compared to the
minimum recorded volume during whatever previous follow-
up time point [3]), maybe a potential sign of malignancy a
further cytological assessment is suggested before
re-treatment.
Level of evidence: 5
Level of agreement: strong (agree, n¼ 29; abstain, n¼ 0;
disagree, n¼ 0)
Statement #10. Thermal ablation may be proposed as a
treatment option for AFTN in patients who refuse or cannot
undergo traditional treatments with radioiodine or surgery.
Summary of evidence: Thermal ablation treatment of
AFTN has been reported to result in volume reduction, symp-
tom amelioration, and improvement or normalization of
hyperthyroidism [10–12,47]. However, the success rate of
thermal ablation in AFTN appears variable and is influenced
by the baseline volume and severity of hyperfunction [13].
Thus, thermal ablation can be proposed as an alternative
treatment only in patients with large AFTN or overt hyper-
thyroidism who refuse or who cannot undergo standard
treatment (i.e., radioiodine or surgery) [11,14,28].
Level of evidence: 2
Level of agreement: strong (agree, n¼ 27; abstain, n¼ 1;
disagree, n¼ 1)
Statement #11. Small size AFTN can be treated with thermal
ablation when the preservation of normal thyroid tissue
function is a priority and it is reasonable to expect at least
80% nodule volume ablation.
Summary of evidence. In case of AFTN, the higher the
ablated volume, the better the functional outcome. Patients
with AFTN are reported to have a higher probability of
symptom resolution and normalization of thyroid function
after thermal ablation if the treatment results in the ablation
of at least 80% of nodule volume [12,14,65–67]. Thus, a
favorable outcome may generally be expected in small AFTN
[66], while in larger nodules a combined treatment with ther-
mal ablation and radioiodine may be planned, as it is
reported resulting in a more rapid volume reduction and in
a lower irradiation than with radioiodine alone [68]. Due to
the lack of changes in the function of the surrounding par-
enchyma and the absence of irradiation, thermal ablation is
specifically appealing in young patients or patients with sub-
clinical hyperthyroidism and incomplete suppression of nor-
mal thyroid tissue [69].
Level of evidence: 3
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Level of agreement: strong (agree, n¼ 27; abstain, n¼ 1;
disagree, n¼ 1)
Discussion
This paper represents the first consensus statement of the
Italian MITT Group regarding the MIT of benign thyroid nod-
ules. For all statements, strong agreement among the mem-
bers of the Group was achieved after the third round of
Delphi process.
Both a robust literature evidence and an ample consensus
among the experts indicated ethanol ablation as the first
treatment modality in case of relapse of cystic nodules after
the aspiration, due to its low-cost, rapidity, and safety. So,
thermal ablation should be reserved only to prevalently cys-
tic lesions that are not controlled by a prior treatment with
ethanol ablation.
Strong agreement was found among the participants
about the need of two consistently benign cytological sam-
ples prior to undergo MIT, as a general rule. Similarly to
what reported in the Korean guideline [38], we evaluated the
opportunity of considering as sufficient a single benign cyto-
logical report. This issue was extensively discussed and the
initial statement was modified, as most experts recom-
mended a second cytological sampling regardless the US
appearance of nodules. Thus, even though at the end of the
process a satisfactory agreement was achieved, we point out
the necessity of controlled studies to better clarify this rele-
vant issue due to the weakness of the available evidence.
Regarding the proposal of MIT as the first treatment
option for benign thyroid nodules, a robust evidence demon-
strates clinically significant and sustained results in most
cases with a very low complication rate. Even though well
conducted comparative studies on the direct and indirect
costs of the two therapeutic approaches are limited, thermal
ablation has the advantage of an outpatient procedure and
lower expenses in comparison with surgery when a single
application is needed. Thus, there is a strong consensus that
MIT should be considered as a first-line treatment for symp-
tomatic solid nonfunctioning benign thyroid nodules that
become symptomatic. So, at variance with former recom-
mendations, MIT should not be reserved only for patients
refusing or who are not suitable for surgery. According to all
experts, MIT represents only a second-line therapeutic option
in multi-nodular goiter and should be reserved only to
patients who are not suitable for surgery.
Regarding follow-up after thermal ablation, there was
strong agreement on the crucial role of ultrasound, which
should be considered as the imaging method of choice.
Other modalities such as color Doppler or contrast-enhanced
ultrasound offer complementary information for better differ-
entiation of the ablated area from the still vital part of the
nodule tissue, but the evidence is still not robust enough to
recommend their routine use in clinical practice.
Strong agreement was achieved on the opportunity of a
repeated treatment for benign thyroid nodules in case of
incomplete symptoms resolution, or if symptoms relapse
after thermal ablation. Presently, there is a lack of studies
specifically addressing the issue of the risk of malignancy in
nodules that re-growth over time after thermal ablation. In
these cases, however, a strong agreement was achieved on
the opportunity of performing a further cytological assess-
ment before a second thermal ablation to rule out the possi-
bility of an underlying malignancy.
The appropriateness of the use of MIT for the manage-
ment of ATFN has been one of the most debated topics dur-
ing the Delphi consensus. Although evidence on the topic is
fair, the clinical role of MITT in clinical practice is still argued.
Specifically, the potential advantages and disadvantages of
MITT versus radioiodine ablation are still not well established
and further controlled studies on this topic are warranted to
better define the appropriate role of MIT in AFTN. Thus, at
present, MIT should be proposed as a treatment option only
in patients who refuse or cannot undergo traditional treat-
ments (i.e., radioiodine ablation or surgery). A strong agree-
ment, however, was reached on the use of thermal ablation
for small AFTN in which the majority of nodule volume (at
least 80%) may be expected to be ablated, as the available
data demonstrate satisfactory results in small size lesions.
Notably, a complete consensus was reached about the pref-
erential use of thermal ablation in young patients or patients
with subclinical hyperthyroidism and incomplete suppression
of normal thyroid tissue in order to spare the function of sur-
rounding normal thyroid tissue.
In conclusion, this consensus document is based on the
assessment of the best available evidence and on the com-
bined opinion of an interdisciplinary group of specialists with
specific interest in thyroid nodules and their minimally-inva-
sive management. After this first proposal for the appropriate
use of MIT in clinical practice, future updates are warranted
on the basis of the improvement of the available evidence.
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